How Psychedelics Can Bend the Mental Health Cost Curve

Psychedelic Researcher and Psychologist Alex Belser, PhD, joins Eric to discuss the efficacy and safety of psychedelics, how they are being applied in practice and the potential pharmacoeconomic and business impact this category of medications can have on patients with severe mental illness.

Alex shares information on the latest research and developments in psychedelics and dispels some of the myths around usage. He also discusses how psychedelics may be more cost-effective than conventional drug treatments for mental health issues and how the medications could change mental health care as we know it.

Alex Belser, PhD

Co-Investigator and Clinical Research Fellow, Yale University

Dr. Alex Belser is a licensed psychologist and researcher focused on psilocybin, MDMA, and DMT therapies. At Yale, Dr. Belser is investigating a psychedelic treatment for OCD. He is the Chief Clinical Officer of Cybin, where he is the co-creator of a new model of psychedelic-assisted psychotherapy called EMBARK.